DNLI:NSD-Denali Therapeutics Inc (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 29.89

Change

-1.69 (-5.35)%

Market Cap

USD 3.87B

Volume

0.93M

Analyst Target

USD 29.18
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-12 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+4.61 (+0.94%)

USD 121.60B
REGN Regeneron Pharmaceuticals Inc

-16.67 (-2.03%)

USD 92.70B
ARGX argenx NV ADR

+5.40 (+0.91%)

USD 35.81B
ALNY Alnylam Pharmaceuticals Inc

-4.35 (-1.62%)

USD 34.69B
BGNE BeiGene Ltd

+1.81 (+0.93%)

USD 22.85B
MRNA Moderna Inc

-1.33 (-3.06%)

USD 21.00B
UTHR United Therapeutics Corporatio..

-0.42 (-0.10%)

USD 16.70B
RPRX Royalty Pharma Plc

-0.15 (-0.58%)

USD 16.11B
INCY Incyte Corporation

-0.10 (-0.12%)

USD 14.67B
SMMT Summit Therapeutics PLC

-1.29 (-6.21%)

USD 13.75B

ETFs Containing DNLI

SBIO ALPS Medical Breakthrough.. 2.50 % 0.50 %

-0.53 (-0.43%)

USD 0.13B
NIXT Research Affiliates Delet.. 1.11 % 0.00 %

-0.12 (-0.43%)

USD 0.03B
XSU:CA iShares US Small Cap (CAD.. 0.00 % 0.36 %

-0.35 (-0.43%)

CAD 0.82B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 39.28% 77% C+ 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 39.28% 77% C+ 84% B
Trailing 12 Months  
Capital Gain 56.25% 74% C 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 56.25% 74% C 83% B
Trailing 5 Years  
Capital Gain 99.27% 83% B 83% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 99.27% 83% B 81% B-
Average Annual (5 Year Horizon)  
Capital Gain 22.40% 66% D+ 75% C
Dividend Return 22.40% 66% D+ 75% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 100.40% 39% F 21% F
Risk Adjusted Return 22.31% 79% B- 56% F
Market Capitalization 3.87B 93% A 86% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector